(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 4.74% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Becton Dickinson & Co's revenue in 2025 is $20,867,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,257,217,934,774, with the lowest BDX revenue forecast at $6,248,821,197,366, and the highest BDX revenue forecast at $6,263,805,032,970. On average, 8 Wall Street analysts forecast BDX's revenue for 2026 to be $6,563,536,487,064, with the lowest BDX revenue forecast at $6,535,795,468,856, and the highest BDX revenue forecast at $6,610,886,611,324.
In 2027, BDX is forecast to generate $6,871,695,058,953 in revenue, with the lowest revenue forecast at $6,824,884,903,061 and the highest revenue forecast at $6,943,924,426,392.